All In Biotech

Drug Trial Radar · NCT04256317

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

A Multi-phase, Pharmacokinetics, Safety, and Efficacy Study of ASTX030 (Azacitidine and Cedazuridine) as Monotherapy in Subjects With Myeloid Neoplasm or in Combination With Venetoclax in Subjects With AML (AZTOUND Study)

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 316 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

316

Planned (sponsor's estimate)

Start

May 21, 2020

Primary completion

Nov 1, 2027

Study completion Nov 1, 2028

Sponsor

Lead sponsor
Taiho Oncology, Inc.Industry
Sponsor type
Industry
First posted
Feb 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms. Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (only one study drug will be escalated at a time) followed by a Dose Expansion Stage (Stage B). Phase 2 Monotherapy is a randomized, open-label, crossover study to compare oral ASTX030 to subcutaneous (SC) azacitidine. Phase 3 Monotherapy is a randomized open-label crossover study comparing the final fixed dose of oral ASTX030 to SC azacitidine. Phase 1 Combination Therapy is an open-label, multicenter, randomized, exploratory study comparing ASTX030 and SC azacitidine in combination with venetoclax in participants with treatment-naïve AML. Phase 2 Combination Therapy is an open-label, single arm, study evaluating the efficacy, safety, pharmacokinetics (PK), and drug interactions of ASTX030 in combination with venetoclax in participants with treatment-naïve AML. The duration of this multi-phase study is approximately 8 years.

Conditions

  • Myelodysplastic Syndromes
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome/Neoplasm
  • Chronic Myelomonocytic Leukemia

Interventions

  • AzacitidineDrug

    Tablets/Capsules for oral administration and powder for reconstitution to aqueous suspension for SC administration.

  • ASTX030 (cedazuridine + azacitidine)Drug

    FDC Capsules for oral administration.

  • AzacitidineDrug

    Powder for reconstitution to aqueous suspension for SC administration.

  • ASTX030 (cedazuridine + azacitidine)Drug

    Tablets/Capsules for oral administration.

  • CedazuridineDrug

    Tablets for oral administration.

  • VenetoclaxDrug

    Oral tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1, 2 and 3 Monotherapy: Total Cycle Area Under the Curve (AUC) From 0 to 24 Hours (AUC0-24) ExposuresTime frame: Predose and at multiple timepoints post-dose up to 24 hours
  2. Phase 1 Combination Therapy: Number of Participants with Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 24 months
  3. Phase 1 and 2 Combination Therapy: Complete Response (CR) Rate as Assessed by the InvestigatorTime frame: Up to 36 months
  4. Phase 1 Combination Therapy: AUC0-24 of Venetoclax With ASTX030Time frame: Pre-dose and at multiple timepoints post-dose up to 24 hours on Day 7 (with ASTX030] of Cycle 1
  5. Phase 1 Combination Therapy: AUC0-24 of Venetoclax Without ASTX030Time frame: Pre-dose and at multiple timepoints post-dose up to 24 hours on Day 14 (without ASTX030) of Cycle 1
  6. Phase 1 Combination Therapy: Maximum Plasma Concentration (Cmax) of Venetoclax With ASTX030Time frame: Pre-dose and at multiple timepoints post-dose up to 24 hours on Day 7 (with ASTX030] of Cycle 1
  7. Phase 1 Combination Therapy: Cmax of Venetoclax Without ASTX030Time frame: Pre-dose and at multiple timepoints post-dose up to 24 hours on Day 14 (without ASTX030) of Cycle 1

Locations

73 sites in 10 countries. Site status is shown where the registry gives one.

  • Keck School of Medicine of USC

    Los Angeles, California · Recruiting

  • UC Irvine Health - Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • University of Miami - Sylvester Comprehensive Cancer Center

    Miami, Florida · Recruiting

  • University of Emory - Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • John Theurer Cancer Center / Hackensack University

    Hackensack, New Jersey · Recruiting

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York · Recruiting

  • New York University Langone Hospital - Long Island

    Mineola, New York · Recruiting

  • Perlmutter Cancer Center - 34th Street

    New York, New York · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • Weill Cornell Medical Center

    New York, New York · Withdrawn

  • Montefiore Medical Center

    The Bronx, New York · Recruiting

  • Duke University

    Durham, North Carolina · Recruiting

  • Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute

    Columbus, Ohio · Recruiting

  • Oregon Health and Science University

    Portland, Oregon · Recruiting

  • Oregon Oncology Specialists

    Salem, Oregon · Recruiting

  • Hollings Cancer Center

    Charleston, South Carolina · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • Baylor Research Institute dba Baylor Scott & White Research Institute

    Dallas, Texas · Withdrawn

  • University of Texas Southwestern Medical Center

    Dallas, Texas · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Seattle Cancer Care Alliance

    Seattle, Washington · Recruiting

  • Froedtert & Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • Eastern Health - Health Sciences Centre

    St. John's, Newfoundland and Labrador, Canada · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

  • Fakultni Nemocnice Ostrava

    Ostrava, Moravian-Silesian, Czechia · Recruiting

  • Fakultní Nemocnice Královské Vinohrady

    Prague, Prague, Czechia · Recruiting

  • Vseobecna Fakultni Nemocnice v Praze

    Prague, Prague, Czechia · Recruiting

  • Institut Universitaire du Cancer de Toulouse (IUCT) Oncopole

    Toulouse, Haute-Garonne, France · Recruiting

  • Hôpital Saint-Louis

    Paris, Île-de-France Region, France · Recruiting

  • Hôpital l'Archet

    Nice, Provence-Alpes-Côte d'Azur Region, France · Recruiting

  • Universitätsklinikum Freiburg

    Freiburg im Breisgau, Baden-Wurttemberg, Germany · Recruiting

  • Universitätsklinikum Heidelberg

    Heidelberg, Baden-Wurttemberg, Germany · Not yet recruiting

  • Städtisches Klinikum Braunschweig

    Braunschweig, Lower Saxony, Germany · Recruiting

  • Universitätsklinikum Halle

    Halle, Saxony-Anhalt, Germany · Recruiting

  • Semmelweis Egyetem Belgyógyászati és Hematológiai Klinika

    Budapest, Hungary · Recruiting

  • Szent-Györgyi Albert Klinikai Központ, II. sz. Belgyógyászati Klinika és Kardiológiai Központ

    Szeged, Csongrád megye, Hungary · Not yet recruiting

  • Petz Aladár Győr-Moson-Sopron Vármegyei Egyetemi Oktató Kórház

    Győr, Győr-Moson-Sopron, Hungary · Recruiting

  • Debreceni Egyetem Klinikai Központ

    Debrecen, Hajdú-Bihar, Hungary · Recruiting

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.